NASDAQ: KODKodiak Sciences Inc Stock
$33.97+2.56 (+8.15%)
Updated Jun 11, 2026
KOD Price
$33.97
Fair Value Price
$2.83
Market Cap
$2.13B
52 Week Low
$3.43
52 Week High
$47.84
P/E
-8.15x
P/B
18.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$230.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.73
Operating Cash Flow
-$147M
Beta
1.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KOD Overview
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KOD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KOD
Ranked#193 of 463
Ranked#193 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important KOD news, forecast changes, insider trades & much more!
KOD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KOD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KOD ($33.97) is overvalued by 1,099.54% relative to our estimate of its Fair Value price of $2.83 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KOD ($33.97) is not significantly undervalued (1,099.54%) relative to our estimate of its Fair Value price of $2.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KOD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KOD due diligence checks available for Premium users.
Valuation
KOD fair value
Fair Value of KOD stock based on Discounted Cash Flow (DCF)
Price
$33.97
Fair Value
$2.83
Overvalued by
1,099.54%
KOD ($33.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KOD ($33.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KOD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KOD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.15x
Industry
17.66x
Market
13.95x
KOD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
18.96x
Industry
4.83x
KOD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KOD's financial health
Profit margin
Revenue
$0.0
Net Income
-$58.2M
Profit Margin
0%
KOD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$306.0M
Liabilities
$193.9M
Debt to equity
1.73
KOD's short-term assets ($175.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KOD's short-term assets ($175.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KOD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KOD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.0M
Investing
-$942.0k
Financing
$619.0k
KOD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KOD vs Biotech Stocks
Kodiak Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.